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ABSTRACT
Objective: To evaluate the extent of HIV-1 drug resistance among drug naïve Kenyan 
individuals.
Design: Cross-sectional study.
Setting: Kenya Medical Research Institute HIV laboratory Nairobi, Kenya.
Subjects: A total of seventy eight HIV-1 positive drug naïve subjects randomised from 
five Kenyan provincial hospitals between April and June 2004.
Results: A major non-nucleoside reverse transcriptase (NNRTI) an associated mutation 
was found in one patient (1.3%). NNRTI associated resistance mutations were present 
at amino acid codon sites G98A (2.56%); K103E (1.3%) and L100F (3.57%) prevalences. 
Baseline resistance may compromise the response to standard NNRTI-based first-line 
ART in 1.3 % of the study subjects.
Conclusion: This indicates in general, that drug resistance among HIV-1 positive drug 
naïve individual is at low thresholds (1.3%) but the problem could be more serious than 
reported here. Continuous resistance monitoring is therefore warranted to maintain 
individual and population-level ART effectiveness. 
INTRODUCTION
HAART therapies have dramatically reduced the 
mortality rate from human immunodeficiency virus 
(HIV) in the developed world (1). Unfortunately, 
current therapies are not curative, and many treated 
patients develop resistance to one or more drugs, 
which is costly and may lead to complete treatment 
failure and death. The drug resistant HIV-1 variants 
emergent in HAART treatment individuals are the 
major obstacle to anti-retroviral therapy and these 
drug resistant variants may be transmitted in newly 
infected individuals (2-3).
 By the end of 2009, it was estimated that there 
were between1.3 and 1.6 million people living with 
HIV/AIDS in Kenya (4). Most of these patients are 
being treated by anti-retroviral treatment regimens 
(5). The provision of treatment has continued to be 
expanded through interventional programs such as 
the World Health Organization’s (WHO’s) 3 by 5 plan 
to treat three million people by the end of 2005 and 
the President’s Emergency Plan for AIDS Relief has 
significantly promoted access to ART in low-income 
and middle-income countries (6-7). As access to ART 
rapidly increases in these resource-limited countries, 
the prevalence of HIV-1 drug-resistant strains among 
drug-naive patients is also expected to increase (7). In 
Kenya, the current standard first-line therapy consists 
of two NRTIs, Azidovudine (AZT) and lamivudine 
(3TC), plus one NNRTI, either nevirapine (NVP) or 
efavirenz (EFV). PI containing regimens are used as 
second line drugs (7).
 The rapid up scaling of ART was accompanied 
by increased availability to those in need, increasing 
to 17% by the end of 2005 (8-9), 31% by 2008 and to 
36% by 2009(4). WHO’s ART guidelines for surveying 
and monitoring HIV drug resistance in resource-
poor countries is being implemented but the high 
cost on constant drug resistance surveillance is 
still a challenge. In addition, the use of single dose 
NVP among HIV-infected antenatal clinic attendees 
influenced the need for laboratory monitoring (10-
11).  Studies have shown cases of acquisition of drug 
resistance mutations among HIV-1 vertically infected 
Kenya children (12). However, there are few reports 
on the magnitude of drug resistance in adults. The 
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current study was conducted to determine the RTI 
resistance-associated mutations among HIV-1-
infected drug naive adults in Kenya where ART is 
being rapidly scaled up. 
MATERIALs ANd METhods
Study population and samples: Individuals who were 18 
years of age or older and who presented themselves 
to the clinic for treatment were considered for 
recruitment after giving informed consent (Table 
1). Patients who reported prior exposure to ART or 
on a single dose NVP for prevention of mother-to-
child transmission (PMTCT) of HIV, together with 
those who declined to consent were excluded from 
the study. A total of 78 HIV positive drug naive 
subjects randomised by computer generation to get 
representative sample of the five Kenyan provincial 
hospitals between April and June 2004 were evaluated. 
These were from Nairobi, Nyanza, Western, Central 
and North Eastern provinces. Five millilitres of blood 
was collected from each participant and tested for 
anti-HIV-1 antibodies using Unigold (Trinity Biotech, 
NY) and Determine (Abbott, IL). HIV-1 antibody 
positivity was further confirmed by enzyme-linked 
immunosorbent assay (ELISA) (Enzygnost, Dade-
Behring, Marburg, Germany). Ethical clearance was 
obtained from the National Ethics Committee through 
the Kenya Medical Research Institute (KEMRI)
National Ethical Review Committee.
PCR and sequencing: Peripheral blood mononuclear 
cells (PBMCs), from confirmed ELISA-positive 
samples, were obtained by Ficoll-Hypaque density 
gradient centrifugation and proviral DNA  extracted 
by  using DNAzol (GIBCO BRL, Life Technologies) 
lysis and ethanol precipitation (7). Briefly, blood was 
mixed with Ficoll-Hypaque and centrifuged with 
breaks to allow separations according to gradient and 
PBMCs separated by pipetting. Subsequently, 500µl 
DNAzol genomic DNA extract reagent (Gibco BRL®) 
was added to PBMCs pellet and mixed gently up and 
down by a pipette. To dissolved pellet, 1ml of cooled 
40C absolute ethanol was added and mixed gently and 
centrifuged at 906xg for 15 minutes. Proviral DNA 
was then precipitated with 70% ethanol, air dried and 
extracted viral DNA resuspended in 100 µl DNAse/
RNase free water.   Nested polymerase chain reaction 
(PCR) was performed using AmpliTaq Gold (Roche 
Molecular Systems, Branchburg, NJ). 
 A segment of the HIV-1 RT gene corresponding 
to nucleotides 2265–3180 of HIV-1HXB2 was amplified 
using the primers RT18 (5’-GGAAACCAAAAAT 
GATAGGGGGAATTGGAGG-3’) and KS104 (5’- 
TGACTTGCCCAATTTAGTTTTCCCACTAA-3’) in 
the first round and KS101 (5’-GTAGGACCTACACC
TGTTCAACATAATTGGAAG-3’) and KS102 (5’-CCC
ATCCAAAGAAATGGAGGAGGTTCTTTCTGATG-
3’) in the second round. Amplification was achieved 
using 1 cycle of 950C for ten minute and 35 cycles of 
950C for 30 s, 550C for 30 s, and 720C for one minute, 
with a final extension of 72oC for ten minute. The 
amplicons were sequenced as previously described 
(7, 12-14).
Genotypic drug resistance analysis: Genotypic drug 
resistance in the pol-RT region was defined as the 
presence of one or more resistance-related mutations, 
as specified by the consensus mutation figures of the 
International AIDS Society-USA (15).
REsuLTs
RTI resistance-associated mutations: Minor RTI 
resistance–associated resistance were found in 1.3% 
of the seventy eight sequences (Table 2). Of these 
sequences one had NNRTI resistance associated 
mutations; at A98G, L100F and K103E codons. The 
detected NNRTI mutations were found from a 
sequence obtained from Nyanza province. In NRTIs, 
no primary nucleoside reverse transcriptase inhibitor 
mutations were detected. Nevertheless, other NRTI 
associated mutations were detected. These were L74F 
(1.3%), Y115I (1.3%), V118G (1.3%), Q151T (1.3%), 
Q151K (1.3%), E44G (1.3%), T69P (1.3%), K70Q 
(1.3%), V75R (1.3%), Y115L (1.3%) and V118G (1.3%) 
prevalences (Table 2). These were detected in only 
four (5.1%) of the subjects under study. 
Table 1 
Baseline Characteristics of HIV-1-Infected Kenyan Patients before Initiating Antiretroviral Therapy
Characteristic  Gender
  All Female Male
  N=78 (n=46) (n = 32)
Age ( years)      
Mean (Range)   35(18-67) 31(18-67) 39(24-55)
CD4+  T cell count (Cells/mm3)      
Mean (Range) 420(100-890) 433(44-800) 399(55-980)
Range      
<300 30 18 12
301-400 15 7 8
400-500 13 6 7
>500 20 8 12
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 Prevalence of mutations-associated with drug resistance findings in HIV-1 positive drug naïve personsa
Drug class N(78%) Mutations positions detected
NNRTI major 1(1.3) A98G, L100F, K103E
NNRTI associated  5(6.4) S3R, E6A, V35T, E36D,  
  K11P, L12F, V35T, K49R,  
  S3R, E6A, K22Q, V35T, E6D,  
  K20R, V21I, V35T, E6D,  
  L12F, G15X, G18X 
NRTI major 0(0) None
NRTI associated  4(5.1) L74F, Y115I, Q151T, Q151K,  
  E44G, T69P, K70Q, V75R,  
  Y115L, V118G
aNRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase 
inhibitor
DISCUSSION
In the current study, the prevalence of mutations that 
confer RTI resistance was found to be 1.3% among 
Kenyan drug-naive individuals sampled in 2004. 
These results assumed no differences in prevalence in 
provinces with small sample used being the reason. 
However compared to recent study conducted on 
samples collected in 2005, the prevalence was 7.5%, 
an indication of possible increase in drug resistance 
probably due to increased coverage for anti-retroviral 
(7). This finding is consistent with other findings 
from countries in Africa that have as well showed 
prevalence to be less than 5% (16-19). However, other 
studies conducted in the recent past have showed over 
5% increase in drug resistance prevalence. Cameroon 
and Mozambique in 2004 showed drug resistance 
prevalence of 9.8 and 5.9% respectively (20-21). The 
difference may be due to the criteria used in the 
different studies. The latter studies were based on the 
WHO’s HIV drug resistance threshold survey (21-22) 
but the former and our study were hospital based, 
that is, among patients seeking treatment.
 In this study, one patient had NNRTI resistance 
mutations. The mutations occurred at codons A98G, 
L100F and K103E positions potentially implicated 
in drug resistance to the non-nucleoside reverse 
transcriptase inhibitor, Nevirapine. The detected 
mutation against Nevirapine meant that the person, 
if treated with Nevirapine might not respond to 
the medication. The mutations detected conferred 
low-level resistance to other NNRTI like Etravirine, 
Efavirence and Delaviridine suggesting that there 
could be low effectiveness of these drugs in persons 
taking them. In NRTIs, no primary nucleoside reverse 
transcriptase inhibitor mutations were detected.
 The NRTI resistance mutations have a higher 
fitness cost for the virus and would not develop in the 
absence of drug pressure (24-25). Although mutations 
conferring NRTI resistance have previously been 
reported among drug naive patients (17, 26-28), the 
possibility that our patients had previous unreported 
contact with anti-retroviral drugs could not be 
excluded. Therefore, considering the limitations of a 
self-reporting system, drug resistance testing would 
be necessary before initiating ART in order to achieve 
a better clinical outcome.
 The prevalence of HIV among Kenyan adults 
has remained relatively steady since 2003, after 
decreasing from a high of 14% in the late 1990s. The 
Kenya demographic and health survey of 2003 found 
a prevalence of 6.7% among individuals aged 15–49 
years (4.6% in men and 8.7% in women) (7, 29), 7.1% 
by 2007 (30), and 6.3% by 2008(4). Access to ART in 
Kenya has significantly increased since the start of 
WHO’s 3 by 5 initiative. The Kenya AIDS indicator 
survey of 2007 showed that of the estimated 392,000 
Kenyan adults in need of ART, 138,000 (35%) had 
received the treatment by September 2007, which 
increased to 212,000 (54%) by June 2008(29). The 
increase in ART coverage is expected to lead to 
an increase in drug-resistant strains among drug-
naive patients. In addition, stigma and cultural 
backgrounds still existing in Kenya may affect ART 
compliance, resulting in an accelerated appearance 
of drug-resistant mutants, which are a potential 
source of transmitted drug resistance (7). It has been 
shown that, not much has been reported on HIV 
drug resistance among drug-naive adults in Kenya, 
though no PI sequencing was completed to assess 
for primary resistance. The observed prevalence of 
mutations conferring drug resistance prompts the 
establishment of strong intervention strategies to keep 
the circulation of drug-resistant strains low. Despite 
the lack of technical capacity (23) and the high cost of 
resistance testing in resource-poor countries, efforts 
Table 2
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to mitigate the impact of the pandemic through the 
surveillance and monitoring of HIV drug resistance 
have proven viable (22). 
 Continuous countrywide surveillance is required to 
determine the magnitude of transmitted drug-resistant 
mutants trends in Kenya. Furthermore, the presence of 
drug resistance mutations in drug-naive persons may 
represent natural polymorphisms of the virus due to 
adaptation mechanisms of the virus due to immune 
pressure and may not be suggestive of transmission of 
drug resistance mutations. The impact of such natural 
polymorphisms on the development of drug resistance 
in those people at commencement of ART is unknown 
and such individuals need to be monitored. Indeed the 
impact of such polymorphisms on the HIV-1 subtypes 
infected population and the speed of more widespread 
drug resistance are also unknown. Therefore it may be 
important to further examine some of the individuals 
and mutations found during this study in view of a 
long-term treatment strategy in the country. This study 
underscores the need to have readily available, high 
through put drug resistance testing for the increasing 
number of infected individuals in order to effectively 
manage those initiating ART. 
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